Skip to contentPart of AbbVie
Organization
Get new research by email Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
Phase 1, Completed, 48 people, Feb 18, 2016
Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin
Phase 1, Completed, 36 people, Feb 18, 2016
Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
Phase 1, Completed, 20 people, Jan 19, 2015
Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
Phase 1, Completed, 20 people, Apr 9, 2013
Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Phase 2, Completed, 143 people, Apr 20, 2011
Sources: clinicaltrials.gov